Day: October 14, 2022

SFE ticker symbol remains the same RADNOR, Pa., Oct. 14, 2022 (GLOBE NEWSWIRE) — Safeguard Scientifics, Inc. (NYSE: SFE) today announced that it will transfer its common stock exchange listing from the New York Stock Exchange to the NASDAQ Capital Market (“NASDAQ”). Safeguard expects to commence trading as a NASDAQ-listed company upon market open on October 26, 2022. Safeguard’s common stock will continue to trade under the ticker symbol SFE. “This transfer to NASDAQ will provide further cost savings for our shareholders and greater corporate flexibility as we pursue portfolio exits and value maximization strategies going forward,” commented Eric Salzman, Chief Executive Officer. About Safeguard Scientifics Historically, Safeguard Scientifics has provided capital and relevant expertise to fuel the growth of technology-driven businesses....

London, October 14, 2022 CNH Industrial N.V. (NYSE: CNHI / MI: CNHI) today announced that its wholly owned subsidiary, CNH Industrial Capital LLC, has completed its previously announced offering of $400 million in aggregate principal amount of 5.450% notes due 2025, with an issue price of 99.349%. The net proceeds of this offering were approximately $395 million after payment of offering and other related expenses. CNH Industrial Capital LLC intends to add the net proceeds from the offering to its general funds and use them for working capital and other general corporate purposes, including, among other things, the purchase of receivables or other assets in the ordinary course of business. The net proceeds may also be applied to repay CNH Industrial Capital LLC’s indebtedness as it becomes due. The notes, which are senior unsecured obligations...

TAIPEI CITY, Oct. 14, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Maxpro Capital Acquisition Corp. (NASDAQ: JMAC) (the “Company”) announced today that its sponsor, MP One Investment LLC (the “Sponsor”), deposited an additional payment in the aggregate amount of $1,035,000 (representing $0.10 per public share) (the “Extension Payment”) into the Company’s trust account for its public stockholders. This deposit enables the Company to extend the date by which the Company has to complete its initial business combination from October 13, 2022 to January 13, 2023 (the “Extension”). The Extension is the first of two three-month extensions permitted under the Company’s governing documents. The Extension provides the Company with additional time to complete its initial business combination with Apollomics Inc. (“Apollomics”), previously announced...

MORRISVILLE, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the appointment of William E. Klitgaard to its Board of Directors. Mr. Klitgaard was previously a member of the Syneos Board from 2017 until May 2022, having resigned due to a personal matter. The Company also announced today that Todd M. Abbrecht is stepping down from its Board of Directors. “We are excited to welcome Bill back to the Syneos Health Board,” said John Dineen, Chair of the Syneos Health Board of Directors. “Bill’s deep financial expertise combined with his knowledge of our company are a welcome addition to an already strong Board, enhancing its composition. This appointment will support continued successful oversight of our strategy as we speed our...

Boston, MA, Oct. 14, 2022 (GLOBE NEWSWIRE) — Progress Acquisition Corp. (“Progress” or the “Company”) (Nasdaq: “PGRW”, “PGRWU”, “PGRWW”) announced the mailing of a definitive proxy statement, dated October 12, 2022 (the “Extension Proxy Statement”), to hold a special meeting in lieu of annual meeting of stockholders (on October 27, 2022 (the “Meeting”) to approve an extension of the date by which Progress must consummate an initial business combination to on or before May 8, 2023 (the “Extended Date”) (the “Charter Extension”). Progress commenced mailing of the Extension Proxy Statement on October 13, 2022. The Meeting will be held virtually on October 27, 2022 at 10:00 AM, Eastern Time and can be accessed by visiting https://www.cstproxy.com/progressacquisition/2022. The Company’s stockholders of record at the close of business...

STEINHAUSEN, Switzerland, Oct. 14, 2022 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) announced today that it will report earnings for the third quarter of 2022, after the close of trading on the NYSE on Wednesday, November 2, 2022. The company will conduct a teleconference to discuss the results starting at 9 a.m. EDT, 2 p.m. CET, on Thursday, November 3, 2022. Individuals who wish to participate should dial +1 785-424-1205 and refer to conference code 260431 approximately 15 minutes prior to the scheduled start time. The teleconference will be simulcast in a listen-only mode at: www.deepwater.com, by selecting Investors, News, and Webcasts. A replay of the conference call will be available after 12 p.m. EDT, 5 p.m. CET, on November 3, 2022. The replay, which will be archived for approximately 30 days, can be accessed at +1 402-220-4975,...

LONGBOAT KEY, Fla., Oct. 14, 2022 (GLOBE NEWSWIRE) — Rumble Inc. (“Rumble”) (NASDAQ: RUM), the video-sharing platform, today announced that it will release financial results for the third quarter of 2022 shortly after market close on Monday, November 14, 2022. The company will host a conference call the same day at 5:00 p.m. Eastern Time. Access to the live webcast and replay of the conference call, along with related earnings release materials, will be available here and on Rumble’s Investor Relations website at investors.rumble.com. About Rumble Rumble is a high-growth neutral video platform that is creating the rails and independent infrastructure designed to be immune to cancel culture. Rumble’s mission is to restore the Internet to its roots by making it free and open once again. For more information, visit corp.rumble.com. For...

SAN DIEGO, Oct. 14, 2022 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced publication in the Cell Press journal Med of data detailing work relating to the discovery and preclinical profiling of STI-9167 neutralizing antibody activity against a broad collection of SARS-CoV-2 variants, including select Omicron subvariants. Protection from Omicron-related disease in vivo in a preclinical challenge model was observed following administration of STI-9167 by the intravenous (IV) route or following administration by the intranasal (IN) route using an intranasal formulation of STI-9167 antibody, termed STI-9199. A link to the publication can be found below: https://www.cell.com/med/fulltext/S2666-6340(22)00321-X About Sorrento Therapeutics, Inc.  Sorrento is a clinical and commercial...